相关实验视频

Updated: Jan 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

膜性病治疗的个性化方法:多中心随机对照试验

Vesna Brglez^1,2,3, Maxime Teisseyre^1,3,4, Kévin Zorzi^1,3

¹Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Nice, France.

EClinicalMedicine

|December 1, 2025

概括

根据表皮质扩散生物标志物指导的脂酶A2受体 (PLA2R1) 膜性病的个性化治疗,与标准护理相比,显著改善了缓解率. 这种方法优化了rituximab治疗以获得更好的患者结果.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
免疫学免疫学免疫学
自免疫性疾病自免疫性疾病

背景情况:

膜性病 (MN) 是一种自身免疫性病,通常与对脂酶A2受体 (PLA2R1) 的自身抗体有关.
针对特定PLA2R1域的免疫反应,称为表位扩散,与MN患者的预后较差和自发缓解率降低相关.
了解这些免疫反应对于开发有效的治疗策略至关重要.

研究的目的:

为了比较标准治疗方案 (GEMRITUX) 与基于PLA2R1表位扩散生物标志物的个性化修仙药治疗策略的疗效.
评估个性化治疗对PLA2R1相关的MN患者12个月后临床缓解率的影响.

主要方法:

一个随机的,前性临床试验,涉及64名在法国12家医院的PLA2R1-MN患者.
患者被分配到标准的GEMRITUX协议或个性化的协议分层治疗,基于基线和六个月的表皮质扩散状态.
主要结局是12个月后部分或完全临床缓解的综合率.

主要成果:

与GEMRITUX组 (35%,p=0.01) 相比,个性化治疗组在12个月内实现了显著更高的临床缓解率 (67%).
个性化治疗与改善功能有关,具体估计的膜过率 (p=0.0498).
两组之间没有发现自发缓解率或不良事件的显著差异,这表明个性化治疗没有导致过度治疗.

结论:

以表位扩散生物标志物为指导的PLA2R1-MN个性化治疗方案在实现临床缓解方面优于标准GEMRITUX协议.
根据免疫严重程度 (表皮层扩散) 对患者进行分层,可以及时和适当地给药瑞图西马布,特别是那些有治疗失败风险的人.
这种基于生物标志物的方法提高了治疗效率,并改善了膜性脏病患者的脏结果.

关键词:

临床试验临床试验是指临床试验的临床试验.皮层正在扩散.膜性脏病是一种膜性脏病.个性化治疗个性化治疗里图西马布 (Rituximab) 是一种药物.

更多相关视频

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...